targetId
stringlengths 15
15
| diseaseId
stringlengths 9
15
| nctid
stringlengths 11
11
⌀ | clinicalStatus
stringclasses 9
values | clinicalPhase
int64 0
4
| studyStartDate
stringlengths 10
10
⌀ | stopStatus
stringclasses 3
values | isStopped
stringclasses 1
value | phase4
stringclasses 1
value | phase3
stringclasses 1
value | phase2
stringclasses 1
value | id
int64 0
1,709B
| why_stopped
stringlengths 2
254
⌀ | phase
stringclasses 7
values | start_date
stringlengths 10
10
⌀ | status
stringclasses 3
values | last_update_posted_date
stringlengths 10
10
⌀ | completion_date
stringlengths 10
10
⌀ | prediction
stringclasses 15
values | metaprediction
stringclasses 6
values | max_l2g
float64 0.05
0.9
⌀ | l2g_075
stringclasses 1
value | l2g_05
stringclasses 1
value | l2g_025
stringclasses 1
value | l2g_01
stringclasses 1
value | l2g_005
stringclasses 1
value | taId
stringclasses 23
values | taLabel
stringclasses 24
values | taLabelSimple
stringclasses 2
values | gc
float64 0
5
⌀ | lof_tolerance
stringclasses 2
values | rnaDistribution
stringclasses 5
values | rnaSpecificity
stringclasses 5
values | partnersBin
stringclasses 4
values | datasourceId
stringclasses 22
values | datatypeId
stringclasses 7
values | total
int64 413k
413k
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ENSG00000065518 | MONDO_0005148 | NCT01702298 | Completed | 3 | 2012-12-07 | null | null | null | Phase III+ | Phase II+ | 609,885,357,727 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01702298 | Completed | 3 | 2012-12-07 | null | null | null | Phase III+ | Phase II+ | 609,885,357,727 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00588172 | Withdrawn | 4 | 2010-06-01 | Withdrawn | stopped | Phase IV | Phase III+ | Phase II+ | 635,655,160,770 | No funding | Phase 4 | 30/06/2010 | Withdrawn | 17/08/2010 | 30/06/2011 | Business_Administrative | Business_Administrative | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00588172 | Withdrawn | 4 | 2010-06-01 | Withdrawn | stopped | Phase IV | Phase III+ | Phase II+ | 635,655,160,770 | No funding | Phase 4 | 30/06/2010 | Withdrawn | 17/08/2010 | 30/06/2011 | Business_Administrative | Business_Administrative | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00588172 | Withdrawn | 4 | 2010-06-01 | Withdrawn | stopped | Phase IV | Phase III+ | Phase II+ | 635,655,160,770 | No funding | Phase 4 | 30/06/2010 | Withdrawn | 17/08/2010 | 30/06/2011 | Business_Administrative | Business_Administrative | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01729403 | Completed | 2 | 2012-12-01 | null | null | null | null | Phase II+ | 635,655,161,682 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01729403 | Completed | 2 | 2012-12-01 | null | null | null | null | Phase II+ | 635,655,161,682 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01729403 | Completed | 2 | 2012-12-01 | null | null | null | null | Phase II+ | 635,655,161,682 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00454233 | Completed | 2 | 2007-02-01 | null | null | null | null | Phase II+ | 661,424,964,354 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00454233 | Completed | 2 | 2007-02-01 | null | null | null | null | Phase II+ | 661,424,964,354 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00454233 | Completed | 2 | 2007-02-01 | null | null | null | null | Phase II+ | 661,424,964,354 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT05226897 | Recruiting | 3 | 2021-07-12 | null | null | null | Phase III+ | Phase II+ | 661,424,965,066 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT05226897 | Recruiting | 3 | 2021-07-12 | null | null | null | Phase III+ | Phase II+ | 661,424,965,066 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT05226897 | Recruiting | 3 | 2021-07-12 | null | null | null | Phase III+ | Phase II+ | 661,424,965,066 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT02853630 | Completed | 4 | 2013-12-01 | null | null | Phase IV | Phase III+ | Phase II+ | 661,424,965,214 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT02853630 | Completed | 4 | 2013-12-01 | null | null | Phase IV | Phase III+ | Phase II+ | 661,424,965,214 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT02853630 | Completed | 4 | 2013-12-01 | null | null | Phase IV | Phase III+ | Phase II+ | 661,424,965,214 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT02791490 | Completed | 3 | 2016-06-16 | null | null | null | Phase III+ | Phase II+ | 661,424,965,407 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT02791490 | Completed | 3 | 2016-06-16 | null | null | null | Phase III+ | Phase II+ | 661,424,965,407 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT02791490 | Completed | 3 | 2016-06-16 | null | null | null | Phase III+ | Phase II+ | 661,424,965,407 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT03169959 | Completed | 1 | 2017-05-29 | null | null | null | null | null | 678,604,832,817 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT03169959 | Completed | 1 | 2017-05-29 | null | null | null | null | null | 678,604,832,817 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT03169959 | Completed | 1 | 2017-05-29 | null | null | null | null | null | 678,604,832,817 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00913367 | Completed | 4 | 2009-05-01 | null | null | Phase IV | Phase III+ | Phase II+ | 678,604,833,338 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00913367 | Completed | 4 | 2009-05-01 | null | null | Phase IV | Phase III+ | Phase II+ | 678,604,833,338 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00913367 | Completed | 4 | 2009-05-01 | null | null | Phase IV | Phase III+ | Phase II+ | 678,604,833,338 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00838903 | Completed | 3 | 2009-02-01 | null | null | null | Phase III+ | Phase II+ | 678,604,833,734 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00838903 | Completed | 3 | 2009-02-01 | null | null | null | Phase III+ | Phase II+ | 678,604,833,734 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00838903 | Completed | 3 | 2009-02-01 | null | null | null | Phase III+ | Phase II+ | 678,604,833,734 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT02813863 | Completed | 1 | 2015-12-01 | null | null | null | null | null | 695,784,703,078 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT02813863 | Completed | 1 | 2015-12-01 | null | null | null | null | null | 695,784,703,078 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT02813863 | Completed | 1 | 2015-12-01 | null | null | null | null | null | 695,784,703,078 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT02836704 | Completed | 4 | 2016-09-09 | null | null | Phase IV | Phase III+ | Phase II+ | 695,784,703,409 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT02836704 | Completed | 4 | 2016-09-09 | null | null | Phase IV | Phase III+ | Phase II+ | 695,784,703,409 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT02836704 | Completed | 4 | 2016-09-09 | null | null | Phase IV | Phase III+ | Phase II+ | 695,784,703,409 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT04943692 | Suspended | 3 | 2021-08-01 | Suspended | stopped | null | Phase III+ | Phase II+ | 695,784,703,649 | Administrative decision of the investigation direction | Phase 3 | 31/08/2021 | Suspended | 29/06/2021 | 31/08/2021 | Business_Administrative | Business_Administrative | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT04943692 | Suspended | 3 | 2021-08-01 | Suspended | stopped | null | Phase III+ | Phase II+ | 695,784,703,649 | Administrative decision of the investigation direction | Phase 3 | 31/08/2021 | Suspended | 29/06/2021 | 31/08/2021 | Business_Administrative | Business_Administrative | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT04943692 | Suspended | 3 | 2021-08-01 | Suspended | stopped | null | Phase III+ | Phase II+ | 695,784,703,649 | Administrative decision of the investigation direction | Phase 3 | 31/08/2021 | Suspended | 29/06/2021 | 31/08/2021 | Business_Administrative | Business_Administrative | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT03445702 | Completed | 0 | 2018-10-15 | null | null | null | null | null | 721,554,506,025 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT03445702 | Completed | 0 | 2018-10-15 | null | null | null | null | null | 721,554,506,025 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT03445702 | Completed | 0 | 2018-10-15 | null | null | null | null | null | 721,554,506,025 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01699932 | Completed | 3 | 2012-09-01 | null | null | null | Phase III+ | Phase II+ | 721,554,506,208 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01699932 | Completed | 3 | 2012-09-01 | null | null | null | Phase III+ | Phase II+ | 721,554,506,208 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01699932 | Completed | 3 | 2012-09-01 | null | null | null | Phase III+ | Phase II+ | 721,554,506,208 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT02926950 | Completed | 3 | 2016-11-01 | null | null | null | Phase III+ | Phase II+ | 721,554,506,661 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT02926950 | Completed | 3 | 2016-11-01 | null | null | null | Phase III+ | Phase II+ | 721,554,506,661 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT02926950 | Completed | 3 | 2016-11-01 | null | null | null | Phase III+ | Phase II+ | 721,554,506,661 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01525225 | Terminated | 1 | 2012-09-01 | Terminated | stopped | null | null | null | 721,554,507,739 | Release of Post Marketing Requirement for this study. Terminated November 2013. | Phase 1 | 30/09/2012 | Terminated | 22/06/2015 | 30/06/2013 | Invalid_Reason | Invalid_Reason | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01525225 | Terminated | 1 | 2012-09-01 | Terminated | stopped | null | null | null | 721,554,507,739 | Release of Post Marketing Requirement for this study. Terminated November 2013. | Phase 1 | 30/09/2012 | Terminated | 22/06/2015 | 30/06/2013 | Invalid_Reason | Invalid_Reason | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01525225 | Terminated | 1 | 2012-09-01 | Terminated | stopped | null | null | null | 721,554,507,739 | Release of Post Marketing Requirement for this study. Terminated November 2013. | Phase 1 | 30/09/2012 | Terminated | 22/06/2015 | 30/06/2013 | Invalid_Reason | Invalid_Reason | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01525225 | Terminated | 1 | 2012-09-01 | Terminated | stopped | null | null | null | 721,554,507,739 | Release of Post Marketing Requirement for this study. Terminated November 2013. | Phase 1 | 30/09/2012 | Terminated | 22/06/2015 | 30/06/2013 | Business_Administrative | Business_Administrative | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01525225 | Terminated | 1 | 2012-09-01 | Terminated | stopped | null | null | null | 721,554,507,739 | Release of Post Marketing Requirement for this study. Terminated November 2013. | Phase 1 | 30/09/2012 | Terminated | 22/06/2015 | 30/06/2013 | Business_Administrative | Business_Administrative | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01525225 | Terminated | 1 | 2012-09-01 | Terminated | stopped | null | null | null | 721,554,507,739 | Release of Post Marketing Requirement for this study. Terminated November 2013. | Phase 1 | 30/09/2012 | Terminated | 22/06/2015 | 30/06/2013 | Business_Administrative | Business_Administrative | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00960661 | Completed | 3 | 2009-09-01 | null | null | null | Phase III+ | Phase II+ | 738,734,376,209 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00960661 | Completed | 3 | 2009-09-01 | null | null | null | Phase III+ | Phase II+ | 738,734,376,209 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00960661 | Completed | 3 | 2009-09-01 | null | null | null | Phase III+ | Phase II+ | 738,734,376,209 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT02033889 | Completed | 3 | 2013-12-13 | null | null | null | Phase III+ | Phase II+ | 738,734,376,915 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT02033889 | Completed | 3 | 2013-12-13 | null | null | null | Phase III+ | Phase II+ | 738,734,376,915 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT02033889 | Completed | 3 | 2013-12-13 | null | null | null | Phase III+ | Phase II+ | 738,734,376,915 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00541450 | Completed | 3 | 2008-01-15 | null | null | null | Phase III+ | Phase II+ | 755,914,244,615 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00541450 | Completed | 3 | 2008-01-15 | null | null | null | Phase III+ | Phase II+ | 755,914,244,615 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00541450 | Completed | 3 | 2008-01-15 | null | null | null | Phase III+ | Phase II+ | 755,914,244,615 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT03138356 | Completed | 1 | 2017-05-25 | null | null | null | null | null | 755,914,244,713 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT03138356 | Completed | 1 | 2017-05-25 | null | null | null | null | null | 755,914,244,713 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT03138356 | Completed | 1 | 2017-05-25 | null | null | null | null | null | 755,914,244,713 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00131664 | Completed | 3 | 2005-09-01 | null | null | null | Phase III+ | Phase II+ | 755,914,245,124 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00131664 | Completed | 3 | 2005-09-01 | null | null | null | Phase III+ | Phase II+ | 755,914,245,124 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00131664 | Completed | 3 | 2005-09-01 | null | null | null | Phase III+ | Phase II+ | 755,914,245,124 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00961480 | Completed | 1 | 2007-10-01 | null | null | null | null | null | 755,914,245,712 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00961480 | Completed | 1 | 2007-10-01 | null | null | null | null | null | 755,914,245,712 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00961480 | Completed | 1 | 2007-10-01 | null | null | null | null | null | 755,914,245,712 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01386671 | Completed | 3 | 2014-06-01 | null | null | null | Phase III+ | Phase II+ | 764,504,178,954 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01386671 | Completed | 3 | 2014-06-01 | null | null | null | Phase III+ | Phase II+ | 764,504,178,954 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01386671 | Completed | 3 | 2014-06-01 | null | null | null | Phase III+ | Phase II+ | 764,504,178,954 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01068652 | Completed | 4 | 2010-03-01 | null | null | Phase IV | Phase III+ | Phase II+ | 764,504,179,424 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01068652 | Completed | 4 | 2010-03-01 | null | null | Phase IV | Phase III+ | Phase II+ | 764,504,179,424 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01068652 | Completed | 4 | 2010-03-01 | null | null | Phase IV | Phase III+ | Phase II+ | 764,504,179,424 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01919489 | Completed | 4 | 2014-03-01 | null | null | Phase IV | Phase III+ | Phase II+ | 764,504,179,507 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01919489 | Completed | 4 | 2014-03-01 | null | null | Phase IV | Phase III+ | Phase II+ | 764,504,179,507 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01919489 | Completed | 4 | 2014-03-01 | null | null | Phase IV | Phase III+ | Phase II+ | 764,504,179,507 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT02004886 | Completed | 2 | 2006-08-11 | null | null | null | null | Phase II+ | 764,504,179,681 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT02004886 | Completed | 2 | 2006-08-11 | null | null | null | null | Phase II+ | 764,504,179,681 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT02004886 | Completed | 2 | 2006-08-11 | null | null | null | null | Phase II+ | 764,504,179,681 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT05054842 | Not yet recruiting | 3 | 2021-10-15 | null | null | null | Phase III+ | Phase II+ | 798,863,917,220 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT05054842 | Not yet recruiting | 3 | 2021-10-15 | null | null | null | Phase III+ | Phase II+ | 798,863,917,220 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT05054842 | Not yet recruiting | 3 | 2021-10-15 | null | null | null | Phase III+ | Phase II+ | 798,863,917,220 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01720290 | Completed | 4 | 2002-07-25 | null | null | Phase IV | Phase III+ | Phase II+ | 798,863,917,479 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01720290 | Completed | 4 | 2002-07-25 | null | null | Phase IV | Phase III+ | Phase II+ | 798,863,917,479 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01720290 | Completed | 4 | 2002-07-25 | null | null | Phase IV | Phase III+ | Phase II+ | 798,863,917,479 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00901979 | Completed | 2 | 2009-04-01 | null | null | null | null | Phase II+ | 798,863,918,059 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00901979 | Completed | 2 | 2009-04-01 | null | null | null | null | Phase II+ | 798,863,918,059 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00901979 | Completed | 2 | 2009-04-01 | null | null | null | null | Phase II+ | 798,863,918,059 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00871936 | Completed | 2 | 2009-04-01 | null | null | null | null | Phase II+ | 798,863,918,737 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00871936 | Completed | 2 | 2009-04-01 | null | null | null | null | Phase II+ | 798,863,918,737 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00871936 | Completed | 2 | 2009-04-01 | null | null | null | null | Phase II+ | 798,863,918,737 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00528372 | Completed | 3 | 2007-09-01 | null | null | null | Phase III+ | Phase II+ | 798,863,919,064 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00528372 | Completed | 3 | 2007-09-01 | null | null | null | Phase III+ | Phase II+ | 798,863,919,064 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00528372 | Completed | 3 | 2007-09-01 | null | null | null | Phase III+ | Phase II+ | 798,863,919,064 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01196546 | Completed | 4 | 2010-03-01 | null | null | Phase IV | Phase III+ | Phase II+ | 824,633,721,121 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01196546 | Completed | 4 | 2010-03-01 | null | null | Phase IV | Phase III+ | Phase II+ | 824,633,721,121 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
Subsets and Splits